Drug Trial Radar · NCT07649369
A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion
Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
Jan 12, 2028
Study completion Aug 14, 2028
Sponsor
- Lead sponsor
- Shanghai Jeyou Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.
Conditions
- Malignant Pleural Effusions (Mpe)
Interventions
JMKX000197Drug
Intrapleural administration
CisplatinDrug
Intrapleural administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Puncture/drainage - Free Survival (PuFS)Time frame: From the date of chest tube removal after the last dose of treatment until the date of next puncture /drainage or date of death from any cause, whichever come first, up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.